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g/10.1016Abstract Reconstruction of the extrahepatic bile duct following bile duct injury or defect is one of
the most common challenges for hepatobiliary surgeons. There are currently a number of surgical
strategies such as biliary-enteric anastomosis, end-to-end anastomosis and autologous tissue substi-
tute. However, sphincter of Oddi dysfunction as well as biliary stricture may occur after surgical
anastomosis. Also, insufﬁcient tissue quantity remains a problem associated with the application
of tissue substitute. Therefore, considerable attention has been attracted to explore a new replace-
ment material of the bile duct for biliary reconstruction. The human umbilical cord (HUC) is abun-
dant in resource and is convenient to collect, including two arteries and one vein, whose diameters
are close to that of the common bile duct. In order to reduce immunogenicity (foreign-body reac-
tion), cells and major histocompatibility complex (MHC) antigens can be removed from the HUC
and the remaining tissue (extracellular matrix, ECM) can be used as a scaffold. The HUC provides
a rich source of mesenchymal stem cells (MSCs). A current study has demonstrated that MSCs are
able to differentiate into biliary epithelial cells in vivo and in vitro with low immunogenicity, which
can be used as seed cells. The HUC might be a promising composite material of a scaffold (ECM)
and seed cells (biliary epithelial cells), for bile duct replacement in situ without removal of sphincter
of Oddi, or biliary stricture. In addition, the patients’ own umbilical cord without any foreign-body
reaction can be directly banked for possible future use in bile duct reconstruction. Therefore, we
hypothesise that the HUC may be a novel substitute for reconstruction of the extrahepatic bile duct.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. epartment of Bile Duct Surgery, West China Hospital, Sichuan University, 37# Guoxue Road,
6 28 85422465.
com (N. Cheng).
ission.
niversity of Medical Sciences. Published by Elsevier Ltd.
h/
/j.jmhi.2012.03.001
Open access under CC BY-NC-ND license. 
8 Y. Cheng et al.Introduction
Bile duct, as a conduit for bile ﬂow, has a poor intrinsic healing
capacity [1,2]. Once bile duct has been affected by carcinoma,
cyst, stricture or atresia, most patients require resection of the
affected segment, if applicable, resulting in iatrogenic bile duct
defect [3]. Iatrogenic bile duct injury occurs more frequently in
the era of laparoscopic cholecystectomy. The overall incidence
of biliary lesion following laparoscopic cholecystectomy varies
between 0.3% and 0.7% in different series [4–7]. Reconstruc-
tion of the extrahepatic bile duct is often performed on the pa-
tients suffering from the bile duct injury or defect [8,9].
Biliary-enteric anastomosis (anastomosis between bile duct
and small intestine) is regarded as the ‘golden standard’ tech-
nique for reconstruction of the extrahepatic bile duct [8,9].
However, this operation alters the normal biliary anatomy
and removes the sphincter of Oddi function, which may lead
to the reﬂux of pancreatic juice and bacteria from the intestine
into the biliary tree [8–10]. Biliary-enteric anastomosis has long
been associated with some severe complications (e.g., cholangi-
tis, anastomotic stricture, intra-hepatic stone and biliary
cirrhosis) and an increased risk for cholangiocarcinoma
[8–10]. Therefore, the best way to treat bile duct injury or de-
fect is to preserve the sphincter of Oddi function and recon-
struct the bile duct in situ without altering the normal biliary
anatomy. However, on account of the present lack of viable
replacement materials with the capacity of growth and regen-
eration, a sphincter of Oddi-preserving biliary reconstruction
remains a challenge for hepatobiliary surgeons [8,9]. Identify-
ing an ideal material that can promote bile duct regeneration
has been an active area of research [8–14].
Recently, the human umbilical cord (HUC) has been
broadly studied in tissue engineering. Current studies have sug-
gested that the HUC has the potential to be used as a substi-
tute for vessel [15–18], ligament, tendon [19] and bone
[20,21]. Furthermore, the use of autologous umbilical vein
patch from ligamentum teres hepatis (round ligament of liver)
for reconstruction of the injured bile duct has been reported in
two small clinical trials [22,23]. Therefore, it may be feasible
that the HUC may be used as a substitute for reconstruction
of the extrahepatic bile duct.
Hypothesis
We hypothesise that the HUC may be an effective novel sub-
stitute for reconstruction of the extrahepatic bile duct. Our
hypothesis can be summarised as follows:
1. Allogenic substitute: An HUC, as a tissue-engineered prod-
uct for reconstruction of the extrahepatic bile duct, is
donated from one person and transplanted into another per-
son. A key in the revolutionary ﬁeld of tissue engineering is
the development of the suitable scaffolds for seeding cells,
growth factors and subsequent growth of tissues. It is well
established that the HUC is rich in conduits (vessels), con-
taining two arteries and one vein. Intriguingly, the HUC
has been demonstrated to be a new source for mesenchymal
stem cells (HUC-MSCs) which can differentiate into multi-
ple lineage-speciﬁc cells that form bone, cartilage, liver, etc
[21,24]. Furthermore, the Wharton’s jelly that surrounds
the human umbilical vein (HUV) is rich in growth factors[25]. HUC, with such a composition of bio-scaffolds, living
cells and growth factors, might be a promising material for
restoration of the function of bile duct.
2. Autologous substitute: The patient’s own umbilical cord,
which was banked after birth for future use, could be
applied to directly reconstruct the patient’s own bile duct.
Some autologous tissues (e.g., vein, ileum and gallbladder)
have been suggested as substitutes for biliary reconstruc-
tion. Similarly, we hypothesise that the autologous HUC
may also be used to reconstruct the bile duct. The autolo-
gous HUC offers the following advantages: First, the
HUC-MSCs might differentiate into biliary epithelial cells
in vivo after transplantation, which might promote the bile
duct regeneration (see below). Second, reconstruction of the
extrahepatic bile duct can be achieved without any immu-
nologic graft rejection.
Both allogenic substitute and autologous substitute can be
used to reconstruct the extrahepatic bile duct in situ without
altering the normal biliary anatomy. This operation does pre-
serve the sphincter of Oddi function. Furthermore, the HUC is
long enough to reconstruct the extrahepatic bile duct more
than once, if necessary (e.g., in case of postoperative anasto-
motic stricture).Evaluation of the hypothesis
The feasibility of this hypothesis is based on the following ﬁve
facts:
1. Scaffolds: The diameters of umbilical vessel and common
bile duct are similar. Mature HUC attains an average diam-
eter of 1.7 cm and a length of 50–60 cm [26,27]. The diam-
eter of umbilical artery varies between 3 and 4 cm, and the
diameter of umbilical vein ranges from 6 to 8 cm [26,27].
The normal common bile duct has a diameter of 6 mm or
less, with a range of 4–8 mm in adults [28,29]. After choos-
ing the umbilical vessels with the appropriate diameter, cells
and major histocompatibility complex (MHC) antigens can
be removed to reduce immunogenicity. The decellularisa-
tion process can be performed via various methods (e.g.,
chemical treatments and enzymatic treatments) [30]. The
remaining tissue consists of mainly extracellular matrix
(ECM). Consequently, tubular scaffold with appropriate
diameter and low immunogenicity can be generated from
the primary HUC. Moreover, the scaffold is biodegradable
and can provide a suitable environment for the growth and
proliferation of stem cells [31].
2. Seed cells: The HCU, especially the part of Wharton’s jelly
and HUC vein, is an abundant resource of mesenchymal
stem cells (HUC-MSCs) [32,33]. It is generally accepted
that HUC-MSCs are poorly immunogenic with multilin-
eage differentiation potential [32,33]. Recently,
HUC-MSCs have successfully differentiated into osteocytes
[21], hepatocytes [24], etc. We have proposed the possibility
of application of bone marrow-derived MSCs in bile leak
[1]. Likewise, the ability of HUC-MSCs to differentiate into
biliary epithelial cells can be postulated.
3. Growth factors: Growth factors are responsible for prolif-
eration and differentiation of cells. For example, epidermal
growth factor (EGF) exerts a wide variety of biological
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entiation of MSCs [34,35]; transforming growth factor beta
(TGF-b) plays important roles in cellular differentiation,
hormone secretion and immune function [34,36]. Fibroblast
growth factor (FGF), EGF and TGF-b have been detected
in the extracts of Wharton’s jelly [25].
4. Animal experiments and clinical trials: An animal experi-
ment has demonstrated the reconstruction of the extrahe-
patic bile duct in dogs by using human amniotic
membrane [14]. As described above, autologous umbilical
vein patch form ligamentum tere hepatis could be used to
reconstruct the injured bile duct [22,23].
5. Sources: The HUC is abundant in resource without ethical
issues. It is usually discarded after delivery. Collecting the
HUC after birth does not carry any risk to the mother or
newborn. Furthermore, some investigators have suggested
the importance of banking the whole umbilical cord unit
for research or future therapeutic use [37].Figure. 1 Strategy of making allogenic substitute. ECMDiscussion
Our strategies of making allogenic substitutes and autologous
substitutes are shown in Figs. 1 and 2. Vascularisation (blood
supply) is a key factor to warrant the long-term viability of the
graft [38]. Various methods have been suggested: incorpora-
tion of vascular endothelial growth factor (VEGF) in the scaf-
fold for slow release; co-cultivation of target tissue cells,
endothelial cells and angiogenesis signalling cells; and decellu-
larisation of the whole organ and its blood vessels [38]. In addi-
tion, wrapping the graft in vascularised great omentum may
support the survival of the graft [14].Conclusion
We hypothesise that the HUC may be a novel substitute for
reconstruction of the extrahepatic bile duct. Continued: extracellular matrix; MSCs: mesenchymal stem cells.
Figure. 2 Strategy of making autologous substitute.
10 Y. Cheng et al.research to establish the ideal HUC scaffold and conﬁrm its
safety and feasibility in animal models will help realise the po-
tential clinical applications of this promising new therapeutic
strategy. Additionally, HUC bank would facilitate the future
use of HUC for reconstruction of the extrahepatic bile duct.
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First question: What do we already know about the
subject?
Reconstruction of the extrahepatic bile duct following
bile duct injury or defect is difﬁcult for surgeons.
Second question: What does your proposed theory add to
the current knowledge available, and what beneﬁts does it
have?
The HUC might be a promising substitute for recon-
struction of bile duct in situ without removal of sphincter
of Oddi, or biliary stricture. This hypothesis provides a
new strategy for bile duct reconstruction.
Third question: Among numerous available studies, what
special further study do you propose for testing the idea?
Continued research to establish the ideal HUC scaf-
fold and conﬁrm its safety and feasibility in animal mod-
els will help realise the potential clinical applications of
this promising new therapeutic strategy.Acknowledgement
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